AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Dec 2020 06:15 PM
RNS
Director/PDMR Shareholding
15 Dec 2020 07:00 AM
RNS
Imfinzi new dose receives positive EU CHMP opinion
14 Dec 2020 07:05 AM
RNS
Trastuzumab deruxtecan positive CHMP
14 Dec 2020 07:00 AM
RNS
Trixeo Aerosphere approved in the EU for COPD
14 Dec 2020 07:00 AM
RNS
AstraZeneca to acquire Alexion Pharmaceuticals Inc
01 Dec 2020 03:00 PM
RNS
Block listing Interim Review
01 Dec 2020 03:00 PM
RNS
Total Voting Rights
01 Dec 2020 07:00 AM
RNS
Crestor to be divested to Grünenthal in Europe
30 Nov 2020 07:00 AM
RNS
Forxiga approved in Japan for heart failure
23 Nov 2020 07:00 AM
RNS
AZD1222 vaccine effective against COVID-19
20 Nov 2020 07:00 AM
RNS
Imfinzi new dosing approved in the US
10 Nov 2020 07:00 AM
RNS
Tezepelumab Phase III trial met primary endpoint
09 Nov 2020 07:00 AM
RNS
Calquence approved in the EU for CLL
06 Nov 2020 07:00 AM
RNS
Brilinta approved in the US in stroke
05 Nov 2020 07:15 AM
RNS
Lynparza approved in the EU for wider ovarian use
05 Nov 2020 07:10 AM
RNS
Lynparza approved in the EU for prostate cancer
05 Nov 2020 07:05 AM
RNS
Forxiga approved in the EU for heart failure
05 Nov 2020 07:00 AM
RNS
AZN: Year-to-date and Q3 2020 results
02 Nov 2020 03:00 PM
RNS
Total Voting Rights
30 Oct 2020 07:00 AM
RNS
Atacand to be divested in more than 70 countries
29 Oct 2020 07:00 AM
RNS
Directorate Change
28 Oct 2020 07:03 AM
RNS
Enhertu US Priority Review in gastric cancer
28 Oct 2020 07:00 AM
RNS
Forxiga CV outcomes benefit approved in China
20 Oct 2020 07:00 AM
RNS
Tagrisso adjuvant lung cancer US Priority Review
19 Oct 2020 07:00 AM
RNS
Forxiga HF receives positive CHMP opinion
19 Oct 2020 07:00 AM
RNS
Trixeo Aerosphere receives positive CHMP opinion
12 Oct 2020 07:00 AM
RNS
COVID-19 antibodies advance and get US funding
02 Oct 2020 07:00 AM
RNS
Farxiga granted US BTD in chronic kidney disease
01 Oct 2020 03:00 PM
RNS
Total Voting Rights
25 Sep 2020 07:00 AM
RNS
Directorate Change
21 Sep 2020 07:05 AM
RNS
Lynparza EU recommendation in prostate cancer
21 Sep 2020 07:00 AM
RNS
Lynparza EU recommendation in ovarian cancer
21 Sep 2020 07:00 AM
RNS
Tagrisso reduced early lung cancer brain recurrenc
10 Sep 2020 07:01 AM
RNS
AstraZeneca to list all US securities on Nasdaq
10 Sep 2020 07:00 AM
RNS
Fasenra PhIII OSTRO trial met co-primary endpoints
01 Sep 2020 03:00 PM
RNS
Total Voting Rights
01 Sep 2020 07:00 AM
RNS
Imfinzi approved in EU for small cell lung cancer
01 Sep 2020 07:00 AM
RNS
Farxiga reduces CKD progression and risk of death
25 Aug 2020 07:00 AM
RNS
Ph I trial begins for COVID-19 monoclonal antibody
21 Aug 2020 07:00 AM
RNS
Imfinzi approved in Japan for SCLC
18 Aug 2020 07:00 AM
RNS
Imfinzi US Priority Review; four-week, fixed dose
04 Aug 2020 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2020 03:00 PM
RNS
Total Voting Rights
30 Jul 2020 07:25 AM
RNS
Tagrisso US BTD for EGFRm adjuvant lung cancer
30 Jul 2020 07:18 AM
RNS
AZN: H1 2020 results
29 Jul 2020 07:00 AM
RNS
Board Committee Changes
28 Jul 2020 07:00 AM
RNS
Farxiga DAPA-CKD trial met all endpoints
27 Jul 2020 07:10 AM
RNS
Calquence receives positive CHMP opinion for CLL
27 Jul 2020 07:05 AM
RNS
Imfinzi recommended for EU approval in SCLC
27 Jul 2020 07:00 AM
RNS
AstraZeneca enters collaboration in oncology
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings